Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered Subcutaneously to Healthy Volunteers [Phase 1]

View source ↗

Summary

This Phase 1 trial update reports on the safety, tolerability, pharmacokinetics, and pharmacodynamics of ISIS 702843 administered subcutaneously to healthy volu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thalassemia

Drugs mentioned

• ISIS 702843

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Thalassemia | Phase 1 | Status: COMPLETED